Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma.
作者信息
Ebia Matthew I, Hitchins Megan P, Hendifar Andrew E
机构信息
Division of Hematology and Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
出版信息
J Gastrointest Oncol. 2023 Apr 29;14(2):1175-1177. doi: 10.21037/jgo-23-12. Epub 2023 Mar 7.
Abstract
摘要
相似文献
1
Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma.错配修复缺陷（dMMR）胰腺导管腺癌的免疫疗法。
J Gastrointest Oncol. 2023 Apr 29;14(2):1175-1177. doi: 10.21037/jgo-23-12. Epub 2023 Mar 7.
2
A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.一例对伊匹单抗和纳武单抗联合治疗有反应的散发性错配修复缺陷型胰腺导管腺癌罕见病例：病例报告
J Gastrointest Oncol. 2023 Feb 28;14(1):458-462. doi: 10.21037/jgo-22-587. Epub 2023 Jan 5.
3
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications.伴有微卫星不稳定性的胰腺导管腺癌的全面特征：组织病理学、分子病理学及临床意义。
Gut. 2021 Jan;70(1):148-156. doi: 10.1136/gutjnl-2020-320726. Epub 2020 Apr 29.
4
Microsatellite instability in pancreatic and ampullary carcinomas: histology, molecular pathology, and clinical implications.胰腺和壶腹癌中的微卫星不稳定性：组织学、分子病理学及临床意义
Hum Pathol. 2023 Feb;132:176-182. doi: 10.1016/j.humpath.2022.06.009. Epub 2022 Jun 14.
5
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites.具有微卫星不稳定性的胰腺癌的组织分子特征：肿瘤内异质性、B2M 失活及转移部位的重要性
Virchows Arch. 2022 Jun;480(6):1261-1268. doi: 10.1007/s00428-021-03205-3. Epub 2021 Oct 6.
6
A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy.一名局部晚期错配修复缺陷型胰腺导管腺癌患者经新辅助免疫治疗成功治愈。
Cureus. 2021 Apr 22;13(4):e14640. doi: 10.7759/cureus.14640.
7
Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection.手术切除治疗的胰腺导管腺癌中错配修复缺陷的免疫组织化学评估。
J Hepatobiliary Pancreat Sci. 2020 Jul;27(7):421-428. doi: 10.1002/jhbp.737. Epub 2020 May 14.
8
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.ESMO 关于免疫治疗中肿瘤微卫星不稳定性检测的建议，及其与 PD-1/PD-L1 表达和肿瘤突变负担的关系：基于系统评价的方法。
Ann Oncol. 2019 Aug 1;30(8):1232-1243. doi: 10.1093/annonc/mdz116.
9
Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review.免疫治疗在表现为错配修复缺陷/高微卫星不稳定/高肿瘤突变负荷的鳞状肺癌患者中的长期获益：病例报告及文献复习。
Front Immunol. 2023 Jan 10;13:1088683. doi: 10.3389/fimmu.2022.1088683. eCollection 2022.
10
Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.在局部晚期错配修复缺陷或微卫星高度不稳定的结直肠癌中使用PD-1抗体进行单药新辅助免疫治疗。
Clin Colorectal Cancer. 2023 Mar;22(1):85-91. doi: 10.1016/j.clcc.2022.11.004. Epub 2022 Nov 25.
引用本文的文献
1
DNA mismatch repair system regulates the expression of PD-L1 through DNMTs in cervical cancer.DNA错配修复系统通过DNA甲基转移酶调节宫颈癌中PD-L1的表达。
Cancer Cell Int. 2024 Jan 10;24(1):25. doi: 10.1186/s12935-024-03214-7.
本文引用的文献
1
A rare case of sporadic mismatch repair deficient pancreatic ductal adenocarcinoma that responded to ipilimumab and nivolumab combination treatment: case report.一例对伊匹单抗和纳武单抗联合治疗有反应的散发性错配修复缺陷型胰腺导管腺癌罕见病例：病例报告
J Gastrointest Oncol. 2023 Feb 28;14(1):458-462. doi: 10.21037/jgo-22-587. Epub 2023 Jan 5.
2
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.胰腺癌：发病机制、筛查、诊断和治疗。
Gastroenterology. 2022 Aug;163(2):386-402.e1. doi: 10.1053/j.gastro.2022.03.056. Epub 2022 Apr 7.
3
Cancer statistics, 2022.癌症统计数据，2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
4
Advances in Pancreatic Ductal Adenocarcinoma Treatment.胰腺导管腺癌治疗进展
Cancers (Basel). 2021 Nov 3;13(21):5510. doi: 10.3390/cancers13215510.
5
Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas.未分化和去分化子宫内膜癌中多种分子特征的临床病理意义。
Pathology. 2021 Feb;53(2):179-186. doi: 10.1016/j.pathol.2020.07.015. Epub 2020 Oct 16.
6
Pancreatic cancer 'mismatch' in Lynch syndrome.林奇综合征中的胰腺癌“错配”
BMJ Open Gastroenterol. 2019 Mar 22;6(1):e000274. doi: 10.1136/bmjgast-2019-000274. eCollection 2019.
7
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.微卫星不稳定性与林奇综合征泛癌的存在相关。
J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30.
8
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1（PD-1）阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.
9
Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.错配修复状态可能预测可切除胰腺导管腺癌对辅助化疗的反应。
Mod Pathol. 2015 Oct;28(10):1383-9. doi: 10.1038/modpathol.2015.89. Epub 2015 Jul 31.
10
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.预计 2030 年美国癌症发病与死亡人数：甲状腺癌、肝癌和胰腺癌带来的意外负担。
Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.
Zotero 插件